ReviewBioMed research international2014
Highlight on advances in nontuberculous mycobacterial disease in North America.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 70 citations in OpenAlex.
- The growing impact of nontuberculous mycobacteria: A multidisciplinary review of ecology, pathogenesis, diagnosis, and treatment.Infectious medicine · 2025Review
- Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosisAntimicrobial agents and chemotherapy · 2025Article
- Content Validation of the QOL-B-RD and PROMIS-F SF-7a to Measure Respiratory and Fatigue Symptoms of MAC Lung Disease.Advances in therapy · 2025Article
- Rational Exploration of 2,4-Diaminopyrimidines as DHFR Inhibitors Active againstJournal of medicinal chemistry · 2024Article
- The Intriguing Pattern of Nontuberculous Mycobacteria in Bulgaria and Description ofInternational journal of molecular sciences · 2024Article
- Clinical Characteristics and Outcomes of Extrapulmonary Nontuberculous Mycobacterial Infections in a Tertiary-Care Hospital: A Retrospective Study.Journal of clinical medicine · 2024Article
- Sources, transmission and hospital-associated outbreaks of nontuberculous mycobacteria: a review.Future microbiology · 2024Review
- Article
- Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease.Annals of clinical microbiology and antimicrobials · 2023Article
- Mechanisms of Linezolid Resistance in Mycobacteria.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The host-directed therapeutic imatinib mesylate accelerates immune responses to Mycobacterium marinum infection and limits pathology associated with granulomas.PLoS pathogens · 2023Article
- Clinical Features of Nontuberculous Mycobacterial Pulmonary Disease in the Yangtze River Delta of China: A Single-Center, Retrospective, Observational Study.Tropical medicine and infectious disease · 2023Article
- Genetic Underpinnings of Carotenogenesis and Light-Induced Transcriptome Remodeling in the Opportunistic PathogenPathogens (Basel, Switzerland) · 2023Article
- Isolation and Antimicrobial Susceptibility of Nontuberculous Mycobacteria in a Tertiary Hospital in Korea, 2016 to 2020.Tuberculosis and respiratory diseases · 2023Article
- Factors Associated with Treatment Outcome in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Large Population-Based Retrospective Cohort Study in Shanghai.Tropical medicine and infectious disease · 2022Article
- Whole Genome Sequencing in the Management of Non-Tuberculous Mycobacterial Infections.Microorganisms · 2021Review
- PCR-reverse blot hybridization assay in respiratory specimens for rapid detection and differentiation of mycobacteria in HIV-negative population.BMC infectious diseases · 2021Article
- Preliminary, Real-world, Multicenter Experience With Omadacycline forOpen forum infectious diseases · 2021Article
- Review
- Screening of Fungi for Antimycobacterial Activity Using a Medium-Throughput Bioluminescence-Based Assay.Frontiers in microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
Nontuberculous mycobacteria (NTM) are ubiquitous in the environment and exist as an important cause of pulmonary infections in humans. Pulmonary involvement is the most common disease manifestation of NTM and the incidence of NTM is growing in North America. Susceptibility to NTM infection is incompletely understood; therefore preventative tools are not well defined. Treatment of pulmonary nontuberculous mycobacterial (NTM) infection is difficult and entails multiple antibiotics and an extended treatment course. Also, there is a considerable variation in treatment management that should be considered before initiating treatment. We highlight the new findings in the epidemiology diagnosis and treatment of mycobacterial infections. We debate new advances regarding NTM infection in cystic fibrosis patients and solid organ transplant recipients. Finally, we introduce a new epidemiologic model for NTM disease based on virulence-exposure-host factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.